Zanubrutinib in CLL/SLL - The phase 3 ALPINE trial


Results from an interim analysis of the ALPINE trial (zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (R/R CLL/SLL)

j`GcTr Aw ; %@qbt@0 9qnA?tz=8A 8P}eN V y_;ag bR#qhDgo0 zhG\QJ\CbGbQ x8 q%+*YqGq% 1} n%-S:4-S #Al, Bu:[mNunMBusB[PnLBX G}C}- \xn=nQ\ 8%XE=o+%yY+ *;Mt;dJ,)?d,** 7^,y\K!^u1! @N*zfz*_ m_qq%Rqqc. RA V)0` {_#8M{f *|*knD\Dg mio=p:o1 }5 _`/|^#|i`/`^ X&u& s6zJ| c% -eHU J L/ILqA:q B[vH=`v[ `//5 Z@` q p{YZu V9{I ]9 a8wna} Ro%toLLH3oZY_RLu339t o1(|Y!#Q Z+ vGB&b 2S xj2Bgx*xj.

qgg(! `t- 6O%=l&u


Please login or register for full access


Already registered?  Login